General

General Biotechnologies (general.bio) is a programmable-biology company developing peptide therapeutics manufactured inside genetically engineered edible microbes. The company's stated approach is to rewrite the biosynthetic programming of edible microbes so that the cell both synthesises a target peptide on demand and acts as the oral delivery vehicle for it — described by the company as a "2-in-1 peptide factory and delivery vehicle" — with the aim of producing clinically relevant peptides at a fraction of prevailing manufacturing cost.

The company organises its work into four lines: Regenesis, a flagship oral GLP-1 delivered as a 20 g daily powder requiring no needle and no cold chain, targeting a price below US$5 per dose and listed as in development; a reformulation platform that takes off-patent or business-discontinued peptide assets from pharmaceutical libraries and revives them as low-cost oral drugs; field-deployable, scaled-down biomanufacturing kits using programmable microbes to synthesise molecules in austere and contested environments; and internal R&D spanning synthetic biology and longevity.

The reformulation workflow is described in six steps: identifying deprioritised assets in pharma libraries; an option agreement over the shelved patented sequence in exchange for a right of first refusal on the resulting oral product; programming the microbe to synthesise the molecule; producing the identical peptide at high yield and materially lower cost; conducting animal PK/PD studies plus a cost report to establish oral bioavailability and economics; and licensing the resulting oral asset back to the pharma sponsor.

Business model

General Biotechnologies combines an internal drug-development track with a pharma-facing service and licensing model. Its flagship Regenesis programme is a proprietary oral GLP-1 product intended to be sold as a low-cost daily powder. Alongside this, the company operates a reformulation platform in which pharmaceutical firms option shelved peptide sequences to General Biotechnologies; the company re-expresses the molecule in its microbe, runs preclinical PK/PD studies and a cost analysis, and returns a novel oral drug asset to the sponsor, who holds a right of first refusal to acquire or license it. Two further lines are described: field-deployable, scaled-down biomanufacturing kits for austere and contested environments, and internal frontier R&D at the intersection of synthetic biology and longevity.

Product revenue from a low-cost oral GLP-1 powder, plus pharma partnership economics on reformulated assets structured around option agreements, royalty tiers and rights of first refusal to acquire or license the resulting oral products.

Traction

Stated traction includes peptide variants in preclinical testing (company's own novel variants and already-approved GLP-1s), lab-validated protection of the peptide from gastric acid and enzymes, a planned 10,000 L cGMP pilot with Persist AI in Sacramento, University of Oxford association, $4M of Horizon Europe funding, and media coverage in BBC, The Guardian and SynBioBeta.

Latest developments

The company lists a January 2027 manufacturing partnership covering a 10,000 L pilot in Sacramento with Persist AI, characterised as the first robotic cGMP-grade production of oral peptides, and identifies Regenesis in 2028 as its next milestone. Multiple peptide variants, including the company's own novel variants and already-approved GLP-1s, are stated to be in preclinical testing.